التجارب السريرية بالأسفل التجارب السريرية الحالية.102 دراسات في أمراض الدم (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Rochester, Minn., Scottsdale/Phoenix, Ariz. This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient. ALEX Study: A Randomized, Phase III Study Comparing Alectinib with Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Scottsdale/Phoenix, Ariz. This randomized, active controlled, multicenter Phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with critozinib treatment in patients with treatment-naive ALK-positive advanced NSCLC. Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive treatment until disease progression, unacceptable toxicity, consent withdrawal or death occurs. The study is expected to last approximately 42 months. A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia Jacksonville, Fla. This open-label, randomized study will compare the efficacy of GDC-0199 plus rituximab (GDC-0199+R) with bendamustine plus MabThera/Rituxan (Rituximab) (B+R) in patients with relapsed or resistant chronic lymphocytic leukemia. Patients will be randomized 1:1 into the two arms. Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2). Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and bendamustine infusions (70 mg/m2) on Days 1 and 2 of each 28-day cycle. Patients in the GDC-0199+R arm will continue GDC-0199 treatment until disease progression or 2 years since treatment start, whichever comes first. Anticipated time on study is up to 5 years. A Blood Collection Protocol to Study the Immune Responses of Cancer Patients with Malignancies Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns of antigen expression: (1) Cohort 1 focuses on cancers displaying a high (80-90%) frequency of MUC1 expression and variably high (unreported to 50%) HER2/neu (“HER2”) expression; (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme (GBM) which often displays the cytomegalovirus tegument protein CMVpp65. Cohort 1 includes blood collections for in vitro studies which are a component of NIH-funded Project 3 within the Mayo Clinic Pancreatic SPORE, “Optimal Immunotargeting of MUC1 for Advanced Pancreatic Cancer” (Principal Investigator Dr. Gendler). Eligibility Criteria, keep current Eligibility Criteria, but precede by:: "Three cohorts of patients will be collected.:Cohort 1 includes (1) advanced unresectable pancreatic cancer, (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype: triple negative [HER2, estrogen and progesterone receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer, (6) advanced, unresectable ovarian cancer, (7) advanced, unresectable clear cell kidney cancer, (8) advanced, unresectable bladder cancer, (9) advanced, unresectable lung adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of residual (macroscopic) disease following an attempt to perform definitive treatment (including surgery, radiation and/or adjuvant or neoadjuvant chemotherapy). Cohort 2 includes (1) muCALR+ primary MF, and (2) muCALR+ secondary MF. Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or recurrent cancers, and may undergo the collection: (1) prior to initiation of systemic therapy; (2) if patient is already engaged in an ongoing cyclical systemic therapy, collection should be within three days prior to the end of the current therapy cycle, if necessary delayed until all clinical parameters are acceptable to proceed with the next planned cycle of therapy; (3) if patient is completing non-cyclical therapy, collection should be at least 2.5-3.0 weeks after completion of the therapy, or delayed until all clinical parameters are acceptable to proceed with any planned follow-up therapy. Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil count ≥ 1,500 /microliter, and platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection. MMRF Molecular Profiling Protocol Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations. A Study of INCB039110 in Combination with Corticosteroids for the Treatment of Acute Graft Versus Host Disease Scottsdale/Phoenix, Ariz. The purpose of this study is to determine if INCB039110 in combination with corticosteroids is safe and tolerable for treating patients with Grade IIB-IVD acute graft-versus-host disease (GVHD). A Study to Explore the Mechanisms that Separate Responders Versus Non-responders to Treatment such as Immunotherapy, Target Therapy and Chemotherapy in Lung Cancer Patients Jacksonville, Fla. The purpose of this study is to explore the underlying mechanisms that distinguishes responder versus non-responders to treatment such as immunotherapy, target therapy and chemotherapy in lung cancer and mechanisms of resistance. The information generated from this study will likely help to design the optimal strategies to improve clinical outcomes in lung cancers. Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the effectiveness of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma. A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to evaluate the safety and tolerability of BMF-500 and to determine the OBD and RP2D of BMF-500. A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma Rochester, Minn., La Crosse, Wis. The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab and lenalidomide (DR) maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in MRD positive patients. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 88 توجّه للصفحة 99 توجّه للصفحة 1010 توجّه للصفحة 1111 التاليالصفحة التالية طلب تحديد موعد الخبرة و مراتب التصنيفالأبحاث 09/05/2023 تبادلها عبر ارسلها على الفيس بوكارسلها في تغريدة أمراض الدمالقسمالرئيسيالأقساممُلخّصالاختبارات والإجراءاتالحالات التي تمَّ علاجهاالأطباءمجموعة متميزةالخبرة و مراتب التصنيفالتجارب السريريةالأبحاثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأقسامطلب موعدمُلخّصالاختبارات والإجراءاتالحالات التي تمَّ علاجهاالأطباءمجموعة متميزةالخبرة و مراتب التصنيفالتجارب السريريةالأبحاثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالة المرضى ORG-20180185 الأقسام والمراكز الطبية أمراض الدم